# CPS Technologies Corp: financial statements, quarterly

CPSH · Nasdaq · CIK 814676 · [Materials](/sectors/materials.md) · fiscal year ends Dec 26

Pages: [Overview](/companies/cpsh.md) · [Financials](/companies/cpsh/financials.md) · [Filings](/companies/cpsh/filings.md) · [Insiders](/companies/cpsh/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/cpsh/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-30) | Q1 FY2024 (2024-03-30) | Q2 FY2024 (2024-06-29) | Q3 FY2024 (2024-09-28) | Q4 FY2024 (2024-12-28) | Q1 FY2025 (2025-03-29) | Q2 FY2025 (2025-06-28) | Q3 FY2025 (2025-09-27) | Q4 FY2025 (2025-12-27) | Q1 FY2026 (2026-03-28) | Q2 FY2026 (2026-06-27) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | [6,285](/filings/0001437749-24-032936.md) | [6,747 d](/filings/0001437749-25-008029.md) | [5,913](/filings/0001437749-25-014320.md) | [5,030](/filings/0001437749-25-024312.md) | [4,247](/filings/0001437749-25-032553.md) | [5,933 d](/filings/0001437749-26-006687.md) | [7,506](/filings/0001437749-26-014881.md) | [8,079](/filings/0001437749-26-027028.md) | [8,804](/filings/0001437749-25-032553.md) | [8,208 d](/filings/0001437749-26-006687.md) | [7,029](/filings/0001437749-26-014881.md) | [8,309](/filings/0001437749-26-027028.md) |
| Cost of revenue | $k | [5,049](/filings/0001437749-24-032936.md) | [5,599 d](/filings/0001437749-25-008029.md) | [5,006](/filings/0001437749-25-014320.md) | [5,260](/filings/0001437749-25-024312.md) | [4,771](/filings/0001437749-25-032553.md) | [6,205 d](/filings/0001437749-26-006687.md) | [6,275](/filings/0001437749-26-014881.md) | [6,742](/filings/0001437749-26-027028.md) | [7,301](/filings/0001437749-25-032553.md) | [6,989 d](/filings/0001437749-26-006687.md) | [6,422](/filings/0001437749-26-014881.md) | [7,081](/filings/0001437749-26-027028.md) |
| Gross profit | $k | [1,236](/filings/0001437749-24-032936.md) | [1,149 d](/filings/0001437749-25-008029.md) | [906](/filings/0001437749-25-014320.md) | [(230)](/filings/0001437749-25-024312.md) | [(523)](/filings/0001437749-25-032553.md) | [(272) d](/filings/0001437749-26-006687.md) | [1,231](/filings/0001437749-26-014881.md) | [1,336](/filings/0001437749-26-027028.md) | [1,503](/filings/0001437749-25-032553.md) | [1,219 d](/filings/0001437749-26-006687.md) | [607](/filings/0001437749-26-014881.md) | [1,229](/filings/0001437749-26-027028.md) |
| Research and development | $k | not reported | not reported | not reported | not reported | not reported | not reported | [868](/filings/0001437749-26-014881.md) | not reported | [900](/filings/0001437749-25-032553.md) | not reported | [217](/filings/0001437749-26-014881.md) | not reported |
| Selling, general and administrative | $k | [1,105](/filings/0001437749-24-032936.md) | [1,005 d](/filings/0001437749-25-008029.md) | [1,166](/filings/0001437749-25-014320.md) | [1,085](/filings/0001437749-25-024312.md) | [963](/filings/0001437749-25-032553.md) | [1,047 d](/filings/0001437749-26-006687.md) | [1,101](/filings/0001437749-26-014881.md) | [1,199](/filings/0001437749-26-027028.md) | [1,226](/filings/0001437749-25-032553.md) | [1,318 d](/filings/0001437749-26-006687.md) | [1,130](/filings/0001437749-26-014881.md) | [1,487](/filings/0001437749-26-027028.md) |
| Operating income | $k | [131](/filings/0001437749-24-032936.md) | [144 d](/filings/0001437749-25-008029.md) | [(260)](/filings/0001437749-25-014320.md) | [(1,315)](/filings/0001437749-25-024312.md) | [(1,486)](/filings/0001437749-25-032553.md) | [(1,319) d](/filings/0001437749-26-006687.md) | [130](/filings/0001437749-26-014881.md) | [137](/filings/0001437749-26-027028.md) | [276](/filings/0001437749-25-032553.md) | [(98.7) d](/filings/0001437749-26-006687.md) | [(523)](/filings/0001437749-26-014881.md) | [(259)](/filings/0001437749-26-027028.md) |
| Income tax | $k | [36.5](/filings/0001437749-24-032936.md) | [84.9 d](/filings/0001437749-25-008029.md) | [(37.3)](/filings/0001437749-25-014320.md) | [(270)](/filings/0001437749-25-024312.md) | [(373)](/filings/0001437749-25-032553.md) | [(279) d](/filings/0001437749-26-006687.md) | [84.2](/filings/0001437749-26-014881.md) | [52.1](/filings/0001437749-26-027028.md) | [114](/filings/0001437749-25-032553.md) | [12.4 d](/filings/0001437749-26-006687.md) | [(82.3)](/filings/0001437749-26-014881.md) | [(150)](/filings/0001437749-26-027028.md) |
| Net income | $k | [171](/filings/0001437749-24-032936.md) | [140 d](/filings/0001437749-25-008029.md) | [(143)](/filings/0001437749-25-014320.md) | [(954)](/filings/0001437749-25-024312.md) | [(1,043)](/filings/0001437749-25-032553.md) | [(995) d](/filings/0001437749-26-006687.md) | [96.0](/filings/0001437749-26-014881.md) | [104](/filings/0001437749-26-027028.md) | [208](/filings/0001437749-25-032553.md) | [12.6 d](/filings/0001437749-26-006687.md) | [(294)](/filings/0001437749-26-014881.md) | [37.7](/filings/0001437749-26-027028.md) |
| Diluted EPS | $ per share | [0.01](/filings/0001437749-24-032936.md) | not reported | [(0.01)](/filings/0001437749-25-014320.md) | [(0.07)](/filings/0001437749-25-024312.md) | [(0.07)](/filings/0001437749-25-032553.md) | not reported | [0.01](/filings/0001437749-26-014881.md) | [0.01](/filings/0001437749-26-027028.md) | [0.01](/filings/0001437749-25-032553.md) | not reported | [(0.02)](/filings/0001437749-26-014881.md) | [0.00](/filings/0001437749-26-027028.md) |
| Basic EPS | $ per share | [0.01](/filings/0001437749-24-032936.md) | not reported | [(0.01)](/filings/0001437749-25-014320.md) | [(0.07)](/filings/0001437749-25-024312.md) | [(0.07)](/filings/0001437749-25-032553.md) | not reported | [0.01](/filings/0001437749-26-014881.md) | [0.01](/filings/0001437749-26-027028.md) | [0.01](/filings/0001437749-25-032553.md) | not reported | [(0.02)](/filings/0001437749-26-014881.md) | [0.00](/filings/0001437749-26-027028.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-30) | Q1 FY2024 (2024-03-30) | Q2 FY2024 (2024-06-29) | Q3 FY2024 (2024-09-28) | FY2024 (2024-12-28) | Q1 FY2025 (2025-03-29) | Q2 FY2025 (2025-06-28) | Q3 FY2025 (2025-09-27) | FY2025 (2025-12-27) | Q1 FY2026 (2026-03-28) | Q2 FY2026 (2026-06-27) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [8.8](/filings/0001437749-24-032936.md) | [8.8](/filings/0001437749-25-008029.md) | [8.7](/filings/0001437749-24-015003.md) | [6.3](/filings/0001437749-24-024434.md) | [4.7](/filings/0001437749-25-032553.md) | [3.3](/filings/0001437749-26-006687.md) | [1.9](/filings/0001437749-26-014881.md) | [2.4](/filings/0001437749-25-024312.md) | [3.2](/filings/0001437749-25-032553.md) | [4.5](/filings/0001437749-26-027028.md) | [5.7](/filings/0001437749-26-014881.md) | [15.4](/filings/0001437749-26-027028.md) |
| Current assets | $m | [19.0](/filings/0001437749-23-030150.md) | [18.1](/filings/0001437749-25-008029.md) | [17.5](/filings/0001437749-24-015003.md) | [15.8](/filings/0001437749-24-024434.md) | [14.7](/filings/0001437749-24-032936.md) | [14.2](/filings/0001437749-26-006687.md) | [14.7](/filings/0001437749-25-014320.md) | [14.9](/filings/0001437749-25-024312.md) | [15.8](/filings/0001437749-25-032553.md) | [24.8](/filings/0001437749-26-027028.md) | [24.0](/filings/0001437749-26-014881.md) | [33.2](/filings/0001437749-26-027028.md) |
| Total assets | $m | [22.5](/filings/0001437749-23-030150.md) | [21.6](/filings/0001437749-25-008029.md) | [21.2](/filings/0001437749-24-015003.md) | [20.1](/filings/0001437749-24-024434.md) | [19.2](/filings/0001437749-24-032936.md) | [18.9](/filings/0001437749-26-006687.md) | [19.2](/filings/0001437749-25-014320.md) | [19.4](/filings/0001437749-25-024312.md) | [20.4](/filings/0001437749-25-032553.md) | [29.5](/filings/0001437749-26-027028.md) | [29.1](/filings/0001437749-26-014881.md) | [38.4](/filings/0001437749-26-027028.md) |
| Current liabilities | $m | [5.1](/filings/0001437749-23-030150.md) | [4.1](/filings/0001437749-25-008029.md) | [3.7](/filings/0001437749-24-015003.md) | [3.5](/filings/0001437749-24-024434.md) | [3.7](/filings/0001437749-24-032936.md) | [4.3](/filings/0001437749-26-006687.md) | [4.5](/filings/0001437749-25-014320.md) | [4.5](/filings/0001437749-25-024312.md) | [5.1](/filings/0001437749-25-032553.md) | [4.7](/filings/0001437749-26-027028.md) | [4.5](/filings/0001437749-26-014881.md) | [4.6](/filings/0001437749-26-027028.md) |
| Total liabilities | $m | [5.4](/filings/0001437749-23-030150.md) | [4.3](/filings/0001437749-25-008029.md) | [3.8](/filings/0001437749-24-015003.md) | [3.6](/filings/0001437749-24-024434.md) | [3.8](/filings/0001437749-24-032936.md) | [4.4](/filings/0001437749-26-006687.md) | [4.5](/filings/0001437749-25-014320.md) | [4.5](/filings/0001437749-25-024312.md) | [5.3](/filings/0001437749-25-032553.md) | [4.9](/filings/0001437749-26-027028.md) | [4.7](/filings/0001437749-26-014881.md) | [4.8](/filings/0001437749-26-027028.md) |
| Long-term debt | $m | [0.1](/filings/0001437749-23-030150.md) | [0.1](/filings/0001437749-24-024423.md) | [0.0](/filings/0001437749-24-015003.md) | [0.0](/filings/0001437749-24-024434.md) | [0.0](/filings/0001437749-24-032936.md) | [0.0](/filings/0001437749-25-008029.md) | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [17.2](/filings/0001437749-24-032936.md) | [17.3](/filings/0001437749-26-006687.md) | [17.3](/filings/0001437749-24-024434.md) | [16.4](/filings/0001437749-25-032553.md) | [15.4](/filings/0001437749-25-032553.md) | [14.5](/filings/0001437749-26-027028.md) | [14.7](/filings/0001437749-26-027028.md) | [14.9](/filings/0001437749-26-027028.md) | [15.1](/filings/0001437749-25-032553.md) | [24.6](/filings/0001437749-26-027028.md) | [24.4](/filings/0001437749-26-027028.md) | [33.7](/filings/0001437749-26-027028.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-30) | Q1 FY2024 (2024-03-30) | Q2 FY2024 (2024-06-29) | Q3 FY2024 (2024-09-28) | Q4 FY2024 (2024-12-28) | Q1 FY2025 (2025-03-29) | Q2 FY2025 (2025-06-28) | Q3 FY2025 (2025-09-27) | Q4 FY2025 (2025-12-27) | Q1 FY2026 (2026-03-28) | Q2 FY2026 (2026-06-27) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [235 d](/filings/0001437749-24-032936.md) | [197 d](/filings/0001437749-25-008029.md) | [129](/filings/0001437749-25-014320.md) | [(1,048) d](/filings/0001437749-25-024312.md) | [(1,187) d](/filings/0001437749-25-032553.md) | [(1,371) d](/filings/0001437749-26-006687.md) | [(1,253)](/filings/0001437749-26-014881.md) | [649 d](/filings/0001437749-26-027028.md) | [1,050 d](/filings/0001437749-25-032553.md) | [(203) d](/filings/0001437749-26-006687.md) | [(292)](/filings/0001437749-26-014881.md) | [(2,230) d](/filings/0001437749-26-027028.md) |
| Capital expenditure | $k | [134 d](/filings/0001437749-24-032936.md) | [151 d](/filings/0001437749-25-008029.md) | [263](/filings/0001437749-25-014320.md) | [552 d](/filings/0001437749-25-024312.md) | [80.1 d](/filings/0001437749-25-032553.md) | [98.4 d](/filings/0001437749-26-006687.md) | [93.1](/filings/0001437749-26-014881.md) | [173 d](/filings/0001437749-26-027028.md) | [174 d](/filings/0001437749-25-032553.md) | [291 d](/filings/0001437749-26-006687.md) | [476](/filings/0001437749-26-014881.md) | [158 d](/filings/0001437749-26-027028.md) |
| Share repurchases | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: not reported

## Shares

| Line item | Unit | Q3 FY2022 (2022-10-01) | Q1 FY2023 (2023-04-01) | Q2 FY2023 (2023-07-01) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-30) | Q2 FY2024 (2024-06-29) | Q3 FY2024 (2024-09-28) | Q1 FY2025 (2025-03-29) | Q2 FY2025 (2025-06-28) | Q3 FY2025 (2025-09-27) | Q1 FY2026 (2026-03-28) | Q2 FY2026 (2026-06-27) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [14.7](/filings/0001437749-23-030150.md) | [14.6](/filings/0001437749-24-015003.md) | [14.6](/filings/0001437749-24-024434.md) | [14.6](/filings/0001437749-24-032936.md) | [14.5](/filings/0001437749-25-014320.md) | [14.5](/filings/0001437749-25-024312.md) | [14.5](/filings/0001437749-25-032553.md) | [14.5](/filings/0001437749-26-014881.md) | [14.6](/filings/0001437749-26-027028.md) | [14.7](/filings/0001437749-25-032553.md) | [18.0](/filings/0001437749-26-014881.md) | [18.9](/filings/0001437749-26-027028.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 19,387,942 at 2026-07-26, from the cover of the [10-Q filed 2026-08-11](/filings/0001437749-26-027028.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:25 ET. No prices; not investment advice.